(Q51069789)

28 March 2018

title

Serum adalimumab concentration and clinical remission in patients with Crohn's disease. (English)

1 reference

28 March 2018

0 references

0 references

1 reference

3

1 reference

28 March 2018

Edouard Louis

4

object named as

Edouard Louis

1 reference

28 March 2018

David T Rubin

2

object named as

David T Rubin

1 reference

28 March 2018

author name string

Yi-Lin Chiu

1

1 reference

28 March 2018

Anne M Robinson

5

1 reference

28 March 2018

Kathleen G Lomax

6

1 reference

28 March 2018

Paul F Pollack

7

1 reference

28 March 2018

Susan K Paulson

8

1 reference

28 March 2018

publication date

1 May 2013

1 reference

28 March 2018

Inflammatory Bowel Diseases

published in

1 reference

28 March 2018

volume

19

1 reference

28 March 2018

issue

6

1 reference

28 March 2018

page(s)

1112-1122

1 reference

28 March 2018

Optimizing the use of tumour necrosis factor inhibitors in Crohn's disease: a practical approach.

cites work

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E3182813242

Tumor necrosis factor: biology and therapeutic inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E3182813242

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E3182813242

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E3182813242

Assessing response and loss of response to biological therapies in IBD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E3182813242

Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E3182813242

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E3182813242

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E3182813242

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E3182813242

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E3182813242

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E3182813242

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E3182813242

Therapeutic drug monitoring of biologics for inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E3182813242

Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E3182813242

A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E3182813242

Elimination mechanisms of therapeutic monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E3182813242

Infliximab, azathioprine, or combination therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E3182813242

10.1097/MIB.0B013E3182813242

21 January 2018

Identifiers

DOI

1 reference

28 March 2018

PubMed ID

23584130

1 reference

28 March 2018